As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win re­view vouch­er

In­vestors re­act­ed neg­a­tive­ly to blue­bird bio’s pric­ing plans for its new sick­le cell ther­a­py, as well as the lack of a valu­able pri­or­i­ty re­view vouch­er and black box warn­ing for the treat­ment.

Fri­day’s FDA ap­proval of blue­bird’s Lyf­ge­nia came two weeks ahead of sched­ule and on the same day Ver­tex Phar­ma­ceu­ti­cals and CRISPR Ther­a­peu­tics land­ed a his­toric clear­ance for Cas­gevy, their CRISPR-based med­i­cine for the same dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER